NCT00362544View on ClinicalTrials.gov

PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia

PHASE4CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

October 31, 2003

Study Completion Date

March 31, 2006

Conditions

Leukemia

Interventions

DRUG

Ambisome

Trial Locations (1)

75015

Gilead Sciences, Paris

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY

NCT00362544 - PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia | Biotech Hunter | Biotech Hunter